Do hospitals get paid for taking part in the CRASH Trial?
• CRASH-2 is funded by the London School of Hygiene & Tropical Medicine (LSHTM) and the World Health Organisation (WHO) and not the manufacturers of tranexamic acid. The funding covers meetings and central organisational costs only. Tranexamic Acid is not a new product. Really large trials of such drugs, involving many hospitals, are important for future patients but are practicable only if those collaborating in them do so without payment (except for recompense of any minor local costs that may arise).
• CRASH-2 is funded by National Institute for Health Research Health Technology Assessment programme (NIHR HTA) and the London School of Hygiene & Tropical Medicine (LSHTM) and not the manufacturers of tranexamic acid. The funding covers meetings and central organisational costs only. Tranexamic Acid is not a new product. Really large trials of such drugs, involving many hospitals, are important for future patients but are practicable only if those collaborating in them do so without payment (except for recompense of any minor local costs that may arise).